Human Reproduction, Vol. 14, No. 7, 1777-1782,
July 1999
© 1999 European Society of Human Reproduction and Embryology
Treatment of autoimmune premature ovarian failure: Case report
1 Section on Women's Health Research, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, 2 National Cancer Institute, Division of Clinical Sciences, Laboratory of Pathology and 3 Warren Grant Magnuson Clinical Center, Diagnostic Radiology Department, National Institutes of Health, Bethesda, MD 20892, USA
There is no known immunosuppressive therapy for autoimmune premature ovarian failure that has been proven safe and effective by prospective randomized placebo-controlled study. Nevertheless, immunosuppression using corticosteroids has been used on an empirical basis for this condition. Here we present two cases of young women with premature ovarian failure who were treated with glucocorticoids in the hopes of restoring fertility. The first case illustrates the potential benefit of such therapy, and the second case illustrates a potential risk. The first patient with histologically proven autoimmune oophoritis was treated with alternate day glucocorticoid treatment. She had return of menstrual bleeding six times and ovulatory progesterone concentrations four times over a 16 week period. The second patient with presumed but unconfirmed autoimmune ovarian failure was referred to us after having been treated with a 9 month course of corticosteroids. During that treatment her menses did not resume. The corticosteroid treatment was complicated by iatrogenic Cushing syndrome and osteonecrosis of the knee. Identifying patients with autoimmune premature ovarian failure presents the opportunity to restore ovarian function by treating these patients with the proper immune modulation therapy. On the other hand, potent immune modulation therapy can have major complications. Corticosteroid therapy for autoimmune premature ovarian failure should be limited to use in placebo-controlled trials designed to evaluate the safety and efficacy of such treatment.
Key words: autoimmune lymphocytic oophoritis/autoimmune premature ovarian failure/glucocorticoids/osteonecrosis/return of ovarian function
4 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. S. Pires, P. P. Parte, P. K. Meherji, S. A. Khan, and V. V. Khole Naturally Occurring Anti-albumin Antibodies Are Responsible for False Positivity in Diagnosis of Autoimmune Premature Ovarian Failure J. Histochem. Cytochem., April 1, 2006; 54(4): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Goswami and G. S. Conway Premature ovarian failure Hum. Reprod. Update, July 1, 2005; 11(4): 391 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Welt, A. Falorni, A. E. Taylor, K. A. Martin, and J. E. Hall Selective Theca Cell Dysfunction in Autoimmune Oophoritis Results in Multifollicular Development, Decreased Estradiol, and Elevated Inhibin B Levels J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3069 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Forges, P. Monnier-Barbarino, G.C. Faure, and M.C. Bene Autoimmunity and antigenic targets in ovarian pathology Hum. Reprod. Update, March 1, 2004; 10(2): 163 - 175. [Abstract] [Full Text] [PDF]
|
|